Market Cap 4.60B
Revenue (ttm) 434.43M
Net Income (ttm) 275.19M
EPS (ttm) N/A
PE Ratio 105.00
Forward PE N/A
Profit Margin 63.35%
Debt to Equity Ratio 0.00
Volume 690,700
Avg Vol 1,220,146
Day's Range N/A - N/A
Shares Out 62.21M
Stochastic %K 33%
Beta 2.20
Analysts Strong Sell
Price Target $76.46

Company Profile

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 474 0170
Address:
7707 Gateway Boulevard, Suite 140, Newark, United States
tic2tape
tic2tape Oct. 24 at 6:47 PM
@JFais $PTGX Do you cover this one? Do you think it is BO? Thanks
1 · Reply
Trapjaw
Trapjaw Oct. 24 at 11:31 AM
$AVTX Cantor #Biotechnology: Today @ 2 PM ET - Panel Discussion with Leading Dermatologists $AVTX $PTGX
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 21 at 5:34 PM
@outlawinvestor1 FYI $MRUS filed their 14D9 this morning that includes, among other things, the revenue forecast provided $GMAB as part of the broader financial projections. You were definitely right again. The MRUS forecasts, especially in the later years, are considerably higher than 3 analysts had projected. I prepared a simple comparison of the 2 showing you snapshots as well. We track these for all commercial-stage bios. It's our experience the projections are closer except for BPMC (BPMC's forecasts were much higher than analysts in the later years). I included an updated comparison of the various revenue multiples versus $PTGX as well. For those interested in clinical-stage bios (and commercial-stage for that matter), may I recommend you follow outlawinvestor1 Otherwise FYI only. This is not investment advice. $IBB $IBBQ
0 · Reply
Camelinvesting
Camelinvesting Oct. 19 at 2:52 PM
$PTGX charte looks decent! Primes for continuation upwards imo
0 · Reply
Quantumup
Quantumup Oct. 17 at 7:30 PM
Citi⬆️ $PTGX's PT to $96 from $72 and kept it at a Buy rating after updating its model and said Rusfertide's De-Risked Profile Supports Upside $JNJ $TAK $BMY $ABVX Citi additionally said:
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 17 at 6:58 PM
@outlawinvestor1 Sean I know little about $PRAX except they raised $525MM from investors after publishing the data yesterday. That is an enormous number in any market. Attached is a comparison of PRAX's valuation versus $MRUS & $PTGX using analyst consensus as of yesterday (before the data was published), as of today excluding the most aggressive forecast and "consensus" that includes the most aggressive forecast. You see PRAX trades at a much lower multiple since revenues are not forecast for some time. Seems to me PRAX is a value should they move forward but I otherwise dislike clinical-stage bio & was hoping you'd take a quick look...or any investor familiar with PRAX. This is not investment advice. $IBB $IBBQ
2 · Reply
JarvisFlow
JarvisFlow Oct. 17 at 3:29 PM
Citigroup has adjusted their stance on Protagonist Therapeutics ( $PTGX ), setting the rating to Buy with a target price of 72 → 96.
0 · Reply
KFace
KFace Oct. 16 at 12:09 AM
$PTGX this aged well 😈😈
1 · Reply
biochirp
biochirp Oct. 15 at 5:43 PM
$FULC $PTGX leak good for JNJ circling back here to get a bolt on deal done?
1 · Reply
Wasthereeverausecase
Wasthereeverausecase Oct. 15 at 12:52 PM
$PTGX this stock will rip to 120 on the next rumour there is a competing bid.
0 · Reply
Latest News on PTGX
Johnson & Johnson in Talks to Buy Protagonist Therapeutics

Oct 10, 2025, 11:13 AM EDT - 15 days ago

Johnson & Johnson in Talks to Buy Protagonist Therapeutics

JNJ


Protagonist Therapeutics Reports Granting of Inducement Award

Apr 16, 2025, 4:05 PM EDT - 6 months ago

Protagonist Therapeutics Reports Granting of Inducement Award


Overlooked Stock: PTGX

Mar 10, 2025, 4:57 PM EDT - 8 months ago

Overlooked Stock: PTGX


Why Is Protagonist Therapeutics Stock Trading Higher On Monday?

Mar 10, 2025, 10:04 AM EDT - 8 months ago

Why Is Protagonist Therapeutics Stock Trading Higher On Monday?


Protagonist Therapeutics Reports Granting of Inducement Awards

Jan 6, 2025, 4:05 PM EST - 10 months ago

Protagonist Therapeutics Reports Granting of Inducement Awards


tic2tape
tic2tape Oct. 24 at 6:47 PM
@JFais $PTGX Do you cover this one? Do you think it is BO? Thanks
1 · Reply
Trapjaw
Trapjaw Oct. 24 at 11:31 AM
$AVTX Cantor #Biotechnology: Today @ 2 PM ET - Panel Discussion with Leading Dermatologists $AVTX $PTGX
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 21 at 5:34 PM
@outlawinvestor1 FYI $MRUS filed their 14D9 this morning that includes, among other things, the revenue forecast provided $GMAB as part of the broader financial projections. You were definitely right again. The MRUS forecasts, especially in the later years, are considerably higher than 3 analysts had projected. I prepared a simple comparison of the 2 showing you snapshots as well. We track these for all commercial-stage bios. It's our experience the projections are closer except for BPMC (BPMC's forecasts were much higher than analysts in the later years). I included an updated comparison of the various revenue multiples versus $PTGX as well. For those interested in clinical-stage bios (and commercial-stage for that matter), may I recommend you follow outlawinvestor1 Otherwise FYI only. This is not investment advice. $IBB $IBBQ
0 · Reply
Camelinvesting
Camelinvesting Oct. 19 at 2:52 PM
$PTGX charte looks decent! Primes for continuation upwards imo
0 · Reply
Quantumup
Quantumup Oct. 17 at 7:30 PM
Citi⬆️ $PTGX's PT to $96 from $72 and kept it at a Buy rating after updating its model and said Rusfertide's De-Risked Profile Supports Upside $JNJ $TAK $BMY $ABVX Citi additionally said:
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 17 at 6:58 PM
@outlawinvestor1 Sean I know little about $PRAX except they raised $525MM from investors after publishing the data yesterday. That is an enormous number in any market. Attached is a comparison of PRAX's valuation versus $MRUS & $PTGX using analyst consensus as of yesterday (before the data was published), as of today excluding the most aggressive forecast and "consensus" that includes the most aggressive forecast. You see PRAX trades at a much lower multiple since revenues are not forecast for some time. Seems to me PRAX is a value should they move forward but I otherwise dislike clinical-stage bio & was hoping you'd take a quick look...or any investor familiar with PRAX. This is not investment advice. $IBB $IBBQ
2 · Reply
JarvisFlow
JarvisFlow Oct. 17 at 3:29 PM
Citigroup has adjusted their stance on Protagonist Therapeutics ( $PTGX ), setting the rating to Buy with a target price of 72 → 96.
0 · Reply
KFace
KFace Oct. 16 at 12:09 AM
$PTGX this aged well 😈😈
1 · Reply
biochirp
biochirp Oct. 15 at 5:43 PM
$FULC $PTGX leak good for JNJ circling back here to get a bolt on deal done?
1 · Reply
Wasthereeverausecase
Wasthereeverausecase Oct. 15 at 12:52 PM
$PTGX this stock will rip to 120 on the next rumour there is a competing bid.
0 · Reply
Quantumup
Quantumup Oct. 14 at 8:50 PM
Clear Street🏁 $WVE Buy/$22: We are initiating coverage of Wave Life Sciences (WVE) with a BUY rating and a $22 PT. $LLY $VKTX $NVO $PTGX ARWR KRRO RNA DYN MRNA Clear Street additionally said:
0 · Reply
kshonstocks
kshonstocks Oct. 14 at 2:17 PM
$PTGX much more likely impatient traders on the wsj story not being finalized yet
0 · Reply
1986iamwallstreet
1986iamwallstreet Oct. 14 at 1:46 PM
$PTGX looks like $JNJ is not buying this
0 · Reply
Fugazi_
Fugazi_ Oct. 14 at 9:32 AM
$PTGX JNJ did not mention this company on ER doubt there is a buy out lol
1 · Reply
StocktwitsNews
StocktwitsNews Oct. 14 at 8:10 AM
Johnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 Print $JNJ $PTGX $LEGN https://stocktwits.com/news/equity/markets/johnson-and-johnson-stock-falls-premarket-investors-q3-print/ch6mSIXR3lw
0 · Reply
StocktwitsNews
StocktwitsNews Oct. 14 at 4:08 AM
BMO Capital Lifts Protagonist Therapeutics Target On J&J Deal Hopes — Retail Traders Pile In $PTGX $JNJ https://stocktwits.com/news/equity/markets/bmo-capital-lifts-protagonist-therapeutics-target-on-jj-deal-hopes/ch6mfAbR3l0
0 · Reply
CrispDry
CrispDry Oct. 13 at 8:20 PM
$PTGX damn I hope this isn’t $SWTX 2.0
2 · Reply
ZacksResearch
ZacksResearch Oct. 13 at 8:19 PM
$PTGX soars 30% on J&J deal buzz — could this be the next big biotech buyout? Reports say J&J is in talks to acquire Protagonist Therapeutics, with negotiations reportedly underway — fueling a massive surge in the stock. Full story on the potential deal here 👉 [link] https://www.zacks.com/stock/news/2767782/protagonist-therapeutics-stock-gains-30-as-jj-reportedly-eyes-deal?cid=sm-stocktwits-2-2535157-teaser-15855&ADID=SYND_STOCKTWITS_TWEET_2_2535157_TEASER_15855
0 · Reply
ZacksResearch
ZacksResearch Oct. 13 at 7:19 PM
$PTGX surges 30% on J&J acquisition rumors! 🚀 $JNJ is reportedly eyeing Protagonist Therapeutics to offset declining Stelara sales and expand in immunology and hematology. With PTGX up 125% YTD, this could be a strategic fit for J&J’s growth. Discover the full story here 👉 https://www.zacks.com/stock/news/2767782/protagonist-therapeutics-stock-gains-30-as-jj-reportedly-eyes-deal?cid=sm-stocktwits-2-2767782-body-15854&ADID=SYND_STOCKTWITS_TWEET_2_2767782_BODY_15854
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Oct. 13 at 7:16 PM
0 · Reply
outlawinvestor1
outlawinvestor1 Oct. 13 at 6:40 PM
$PTGX great buying opportunity. silly retail believing that ptgx would sell itself for < $5 billion.
0 · Reply
kshonstocks
kshonstocks Oct. 13 at 6:37 PM
Apparently betaville is the reason for the air pocket on $PTGX https://x.com/doepke_michel/status/1977784765857013997
0 · Reply